WoodTrust Financial Corp Has $1.39 Million Stake in Zoetis Inc. (NYSE:ZTS)

WoodTrust Financial Corp raised its stake in Zoetis Inc. (NYSE:ZTS) by 10.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,236 shares of the company’s stock after buying an additional 756 shares during the quarter. WoodTrust Financial Corp’s holdings in Zoetis were worth $1,393,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC lifted its stake in Zoetis by 1.2% in the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after buying an additional 52 shares during the period. Forum Financial Management LP increased its holdings in shares of Zoetis by 0.8% in the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after acquiring an additional 56 shares in the last quarter. Angeles Wealth Management LLC increased its holdings in shares of Zoetis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after acquiring an additional 56 shares in the last quarter. Prossimo Advisors LLC increased its holdings in shares of Zoetis by 1.7% in the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares in the last quarter. Finally, River Street Advisors LLC increased its holdings in shares of Zoetis by 3.4% in the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 1.8 %

Shares of NYSE:ZTS traded down $3.10 during trading on Friday, hitting $173.36. 4,189,580 shares of the company were exchanged, compared to its average volume of 2,374,760. The stock has a market cap of $79.10 billion, a price-to-earnings ratio of 33.40, a P/E/G ratio of 2.74 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a fifty day moving average price of $168.69 and a two-hundred day moving average price of $178.81. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.31 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZTS. Stifel Nicolaus lowered their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group decreased their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. HSBC decreased their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, Barclays decreased their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.